James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Posted by Joseph Griffin on Jun 18th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $549.17, for a total transaction of $5,491,700.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,366,132.92. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $549.29, for a total transaction of $5,492,900.00.
On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total transaction of $5,475,000.00.
On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00.
On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total transaction of $5,478,700.00.
On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total transaction of $5,656,300.00.
On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total transaction of $5,729,400.00.
On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total transaction of $5,641,100.00.
On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total transaction of $5,673,100.00.
On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00.
On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total transaction of $5,730,300.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $551.47 on Thursday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm has a market cap of $23.41 billion, a PE ratio of 20.36, a PEG ratio of 1.79 and a beta of 0.57. The company has a 50 day simple moving average of $565.95 and a two-hundred day simple moving average of $522.96.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the firm earned $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its holdings in United Therapeutics by 2.8% during the 1st quarter. Parallel Advisors LLC now owns 1,056 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 29 shares during the last quarter. NewEdge Advisors LLC raised its holdings in United Therapeutics by 24.7% during the 1st quarter. NewEdge Advisors LLC now owns 2,163 shares of the biotechnology company’s stock valued at $1,283,000 after buying an additional 428 shares during the last quarter. Janus Henderson Group PLC raised its holdings in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the last quarter. Bull Harbor Capital LLC bought a new stake in United Therapeutics during the 1st quarter valued at $494,000. Finally, Strategic Investment Advisors MI raised its holdings in United Therapeutics by 20.5% during the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after buying an additional 1,662 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on UTHR shares. Bank of America upped their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Finally, UBS Group upped their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $619.42.

View Our Latest Research Report on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.